News related to Acular (Ketorolac Ophthalmic) and/or conditions it is approved for
Macular degeneration insight identifies promising drugs to prevent vision loss
Source: Eye Health / Blindness News From Medical News Today [2016.07.20]
In a study published in the Proceedings of the National Academy of Sciences, a University of Wisconsin-Madison research team pinpoints how immune abnormalities beneath the retina result in macular...
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2016.05.06]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 12:00:00 AM
Last Editorial Review: 5/6/2016 12:00:00 AM
Patients with macular degeneration show improvement with high-dose statin treatment
Source: Statins News From Medical News Today [2016.02.05]
Researchers at Massachusetts Eye and Ear/Harvard Medical School and the University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins (cholesterol-lowering...
Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.
'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010
Legions of nanorobots target cancerous tumours with precision
Source: Cancer / Oncology News From Medical News Today [2016.08.16]
Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research.
Gene therapy in a droplet could treat eye diseases, prevent blindness
Source: Eye Health / Blindness News From Medical News Today [2016.07.28]
Eye diseases such as diabetic retinopathy and age-related macular degeneration are among the leading causes of irreversible vision loss and blindness worldwide.
Ruboxistaurin (RBX) may reduce risk of vision loss in diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
Phase III trial demonstrates ruboxistaurin (RBX) may reduce the risk of vision loss especially in diabetic macular edema.